Inhibitor idelalisib active in non-Hodgkin lymphoma

Share this content:
Idelalisib Active in Non-Hodgkin's Lymphoma
Idelalisib Active in Non-Hodgkin's Lymphoma

(HealthDay News) -- The phosphatidylinositol-3-kinase delta (PI3Kδ) inhibitor idelalisib shows antitumor activity in patients with indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia (CLL), according to two studies published in the March 13 issue of the New England Journal of Medicine.

Ajay K. Gopal, M.D., from the University of Washington School of Medicine in Seattle, and colleagues conducted a phase 2 study of idelalisib involving 125 patients with previously treated indolent non-Hodgkin's lymphomas. The researchers found that the response rate was 57 percent overall, and 6 percent of patients met complete response criteria. The median time to response, duration of response, and progression-free survival were 1.9, 12.5, and 11 months, respectively. Response rates were similar across all subtypes of indolent non-Hodgkin's lymphoma.

Richard R. Furman, M.D., from Weill Cornell Medical College in New York City, and colleagues examined the efficacy and safety of idelalisib in combination with rituximab versus rituximab plus placebo for 220 patients with relapsed CLL with clinically significant coexisting medical conditions. The researchers found that the median progression-free survival was not reached in the idelalisib group and was 5.5 months in the placebo group (hazard ratio for progression or death, 0.15; P < 0.001). In the idelalisib group, the rates of overall response (81 versus 13 percent; odds ratio, 29.92) and overall survival at 12 months (92 versus 80 percent; hazard ratio, 0.28) were significantly increased.

"The emerging success of idelalisib illustrates the clinical translation of basic research studies of PI3K signaling in B cells," write the authors of an accompanying editorial.

Both studies were funded by Gilead Sciences, the manufacturer of idelalisib.

Full Text - Gopal (subscription or payment may be required)
Full Text - Furman (subscription or payment may be required)
Editorial (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs